In this series of experiments, we sought to determine if shorter-term, sub-chronic treatment (4 weeks) with the RyR inhibitor, dantrolene, is an effective strategy to normalize early pathogenic Ca2+ signaling and related synaptic transmission and plasticity deficits observed, as well as amyloid deposition, in the AD mice. The gene discussed is RYR1; the disease is Alzheimer disease.